MarketPulse

phase 2 trial

19 articles
GlobeNewswire Inc.GlobeNewswire Inc.··Na

Acumen Pharma to Present Alzheimer's Drug Data at BofA Conference

Acumen Pharma to present at BofA Securities conference May 14 ahead of late-2026 Alzheimer's drug trial results.
ABOSmonoclonal antibodyclinical-stage biopharmaceutical
GlobeNewswire Inc.GlobeNewswire Inc.··Na

Incannex Healthcare Wins MedTech Prize for Sleep Apnea Drug IHL-42X

Incannex Healthcare wins MedTech Breakthrough Award for IHL-42X sleep apnea therapy, validated by successful Phase 2 trial results showing significant improvements in key endpoints.
IXHLclinical developmentdrug development
GlobeNewswire Inc.GlobeNewswire Inc.··Not Specified

Maze Therapeutics Raises $150M to Fund Late-Stage Drug Pipeline Through 2029

Maze Therapeutics prices $150M offering at $23.50/share, securing funding through 2029 for kidney disease and PKU programs.
MAZEclinical developmentcapital raise
GlobeNewswire Inc.GlobeNewswire Inc.··Na

Disc Medicine to Present Breakthrough Anemia Data for DISC-0974 at ASCO 2026

Disc Medicine to present Phase 2 DISC-0974 data showing unprecedented anemia response rates in myelofibrosis at ASCO 2026, potentially reshaping treatment landscape.
IRONphase 2 trialclinical trial data
GlobeNewswire Inc.GlobeNewswire Inc.··Na

Cardiff Oncology to Present Onvansertib Phase 2 Data at ASCO 2026

Cardiff Oncology will present updated Phase 2 data for onvansertib in RAS-mutated colorectal cancer at ASCO 2026 in June.
CRDFcolorectal cancerphase 2 trial
GlobeNewswire Inc.GlobeNewswire Inc.··Na

Obesity Biotech Kailera Prices IPO at $16/Share, Eyes $625M Raise

Clinical-stage biotech Kailera prices IPO at $16/share, raising $625M. Company debuts on Nasdaq ($KLRA) April 17 with positive Phase 2 obesity drug data.
JHPCYIPObiotechnology
GlobeNewswire Inc.GlobeNewswire Inc.··Not Specified

Evaxion's Personalized Cancer Vaccine Shows 75% Response Rate in Extended Trial

Evaxion completes Phase 2 extension of personalized cancer vaccine EVX-01 with 75% response rate and 92% durability at two years.
MRKEVAXphase 2 trialimmunotherapy
GlobeNewswire Inc.GlobeNewswire Inc.··Adagene Inc.

Adagene Posts Promising ADG126 Data With $74.5M Cash Runway Into 2028

Adagene reports 29% response rate for ADG126 in colorectal cancer with improved safety profile. Company maintains $74.5M cash reserves extending runway into early 2028.
MRKSNYRHHBYADAGcolorectal cancerclinical trial
GlobeNewswire Inc.GlobeNewswire Inc.··Na

Rapport Therapeutics to Unveil RAP-219 Phase 2 Data for Seizure Treatment

Rapport Therapeutics will present Phase 2a follow-up data for experimental seizure drug RAP-219 at neurology conference in April 2026.
RAPPprecision medicinephase 2 trial
BenzingaBenzinga··Globe Newswire

SCYNEXIS Expands Pipeline With $8M PXL-770 Acquisition, Eyes Rare Kidney Disease Market

SCYNEXIS completes acquisition of PXL-770 AMPK activator for ADPKD treatment. Deal includes $8M upfront, up to $188M milestones; Phase 2 study planned for late 2026.
GSKSCYXacquisitionclinical development
GlobeNewswire Inc.GlobeNewswire Inc.··Na

Biogen's Lupus Drug Shows Promise Again, Edges Closer to Historic FDA Approval

Biogen announces second positive Phase 2 trial of litifilimab for cutaneous lupus, showing 11.8% greater disease reduction than placebo, advancing toward potential first targeted CLE therapy in 70 years.
BIIBFDA Breakthrough Therapy Designationclinical trial results
BenzingaBenzinga··Vandana Singh

Novo Nordisk's Experimental Obesity Drug Shows Superior Results to Semaglutide

Novo Nordisk and United Biotechnology's experimental drug UBT251 outperformed semaglutide in phase 2 trials, delivering stronger weight loss and glucose control.
LLYNVOweight losssemaglutide
The Motley FoolThe Motley Fool··Lee Samaha

Ovid Therapeutics Surges 18% on Positive Phase 1 Data for OV329 Epilepsy Drug

Ovid Therapeutics surges 18% after Phase 1 data shows OV329 epilepsy drug eliminated safety concerns. Company secures $60M to fund Phase 2 trials.
OVIDbiotechprivate placement
BenzingaBenzinga··Vandana Singh

Pfizer's Breast Cancer Drug Hits Survival Goals as Oncology Pipeline Accelerates

Pfizer reports positive Phase 2 data for atirmociclib in metastatic breast cancer, meeting survival endpoints. Company also gains FDA approval for Braftovi in colorectal cancer.
PFEcolorectal cancerFDA approval
GlobeNewswire Inc.GlobeNewswire Inc.··Na

Allarity Therapeutics Secures $20M Funding to Accelerate Stenoparib FDA Path

Allarity Therapeutics secures $20M non-dilutive debt financing to complete stenoparib Phase 2 trial and advance toward FDA approval, extending runway to mid-2028.
ALLRFDA approvaldebt financing
BenzingaBenzinga··Vandana Singh

Roche's Obesity Drug Falls Short of GLP-1 Rivals in Phase 2 Results

Roche's obesity drug petrelintide achieved 10.7% weight loss in Phase 2 trials but significantly trails GLP-1 rivals Novo Nordisk and Eli Lilly, triggering sharp stock declines.
LLYNVORHHBYclinical trial resultsweight loss
BenzingaBenzinga··Vandana Singh

Novo Nordisk's China Obesity Treatment Achieves 19.7% Weight Loss in Phase 2 Trial

Novo Nordisk's obesity drug UBT251 achieved 19.7% weight loss in Phase 2 trials for Chinese patients, offsetting recent setbacks from a failed competitor drug trial.
LLYNVOclinical trialweight loss
GlobeNewswire Inc.GlobeNewswire Inc.··Macrogenics, Inc.

MacroGenics Halts New Patient Enrollment in LINNET Trial Following FDA Clinical Hold

FDA places partial clinical hold on MacroGenics' LINNET trial due to serious adverse events including thrombocytopenia, myocarditis, and one death. New enrollment halted.
MGNXFDA clinical holdbispecific antibody
GlobeNewswire Inc.GlobeNewswire Inc.··Na

Protara Therapeutics to Present TARA-002 Data at Major Medical Conferences

Protara Therapeutics will present TARA-002 Phase 2 interim data at ASCO GU Symposium, showcasing results for BCG-unresponsive bladder cancer treatment.
TARAinvestor conferencebladder cancer